Obstetric-Fetal Pharmacology Research Centers

The status of pharmacometrics in pregnancy: Highlights from the 3rd American Conference on Pharmacometrics

van Hasselt, J. G., Andrew, M. A., Hebert, M. F., Tarning, J., Vicini, P., & Mattison, D. R. (2012). The status of pharmacometrics in pregnancy: Highlights from the 3rd American Conference on Pharmacometrics. British Journal of Clinical Pharmacology, 74(6), 932-9. doi: 10.1111/j.1365-2125.2012.04280.x. (PMID: 22452385)

Pharmacokinetics of tacrolimus during pregnancy

Zheng, S., Easterling, T. R., Umans, J. G., Miodovnik, M., Calamia, J. C., Thummel, K. E., Shen, D. D., Davis, C. L., & Hebert, M. F. (2012). Pharmacokinetics of tacrolimus during pregnancy. Therapeutic Drug Monitoring, 34(6), 660-70. doi: 10.1097/FTD.0b013e3182708edf. (PMID: 23007747)

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Caritis, S. N., Sharma, S., Venkataraman, R., Hankins, G., Miodovnik, M., Hebert, M. F., Umans, J. G., Benedetti, T., Mattison, D., Zajicek, A., Fischer, D., Jackson, A., & Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units Network (2012). Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology, 207(5), 398.e1–8. doi: 10.1016/j.ajog.2012.08.015. (PMID: 22967833)

Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Haas, D. M., & D’Alton, M. (2012). Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?. Obstetrics and Gynecology, 120(5), 1176-9. doi: 10.1097/AOG.0b013e3182698538. (PMID: 23090536)

Transplacental transfer of oseltamivir carboxylate

Nanovskaya, T. N., Patrikeeva, S. L., Zhan, Y., Hankins, G. D., & Ahmed, M. S. (2012). Transplacental transfer of oseltamivir carboxylate. The Journal of Maternal-Fetal & Neonatal Medicine, 25(11), 231-5. doi: 10.3109/14767058.2012.693993. (PMID: 22590979)

Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy

Costantine, M. M., Matok, I., Chiossi, G., Clark, S., Miodovnik, M., Umans, J. G., Caritis, S., Hankins, G. D. V., & Koren, G. (2012). Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. Therapeutic Drug Monitoring, 34(5), 569-73. (PMID: 22972538)

Tocolytic therapy for preterm delivery: A systematic review and network meta-analysis

Haas, D. M., Caldwell, D. M., Kirkpatrick, P., McIntosh, J. J., & Welton, N. J. (2012). Tocolytic therapy for preterm delivery: A systematic review and network meta-analysis. BMJ, 345, e6226, doi: 10.1136/bmj.e6226. (PMID: 23048010)

Transplacental transfer of vancomycin and telavancin

Nanovskaya, T. N., Patrikeeva, S. L., Zhan, Y., Fokina, V. M., Hankins, G. D., & Ahmed, S. (2012). Transplacental transfer of vancomycin and telavancin. American Journal of Obstetrics and Gynecology, 207(4), 331.e1-6. doi: 10.1016/j.ajog.2012.06.064. (PMID: 22867688)

The current state of therapeutic drug trials in pregnancy

Endicott, S., & Haas, D. M. (2012). The current state of therapeutic drug trials in pregnancy. Clinical Pharmacology and Therapeutics, 92(2), 149-50. doi: 10.1038/clpt.2012.81. (PMID: 22814658)

The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use

Haas, D. M., Lehmann, A. S., Skaar, T., Philips, S., McCormick, C. L., Beagle, K., Hebbring, S. J., Dantzer, J., Li, L., & Jung, J. (2012). The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use. American Journal of Obstetrics and Gynecology, 206(5), 447.e17-24. doi: 10.1016/j.ajog.2012.02.016. (PMID: 22445700)

A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic

Haas, D. M., Quinney, S. K., McCormick, C. L., Jones, D. R., & Renbarger, J. L. (2012). A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. The Journal of Maternal-Fetal & Neonatal Medicine, 25(4), 419-23. doi: 10.3109/14767058.2011.583700. (PMID: 21644845)

Metabolism of 17alpha-hydroxyprogesterone caproate by human placental mitochondria

Fokina, V. M., Zharikova, O. L., Hankins, G. D., Ahmed, M. S., & Nanovskaya, T. N. (2012). Metabolism of 17alpha-hydroxyprogesterone caproate by human placental mitochondria. Reproduction Science, 19(3), 290-7. doi: 10.1177/1933719111419248. (PMID: 22138546)

Review of NVP and HG and early pharmacotherapeutic intervention

Clark, S. M., Costantine, M. M., & Hankins, G. D. V. (2012). Review of NVP and HG and early pharmacotherapeutic intervention. Obstetrics and Gynecology International, Volume 2012 (2012), Article ID 252676, doi: 10.1155/2012/252676. (PMID: 22190950)

Pharmacogenetics of obstetric therapeutics

Haas, D. M., & Renbarger, J. L. (2012). Pharmacogenetics of obstetric therapeutics. In R. B. Altman, D. Flockhart, & D. B. Goldstein (Eds.), Principles of pharmacogenetics and pharmacogenomics (pp. 202-216). Cambridge: Cambridge University Press.

Increased apoptosis in chorionic trophoblasts of human fetal membranes with labor at term

Harirah, H. M., Borahay, M. A., Zaman, W., Ahmed, M. S., & Hankins, G. D. (2012). Increased apoptosis in chorionic trophoblasts of human fetal membranes with labor at term. International Journal of Clinical Medicine, 3, 136-142.

Drugs during pregnancy and lactation: New solutions to serious challenges

Koren, G., Clark, S., & Matsui, D. (2012). Drugs during pregnancy and lactation: New solutions to serious challenges. Obstetrics and Gynecology International, Volume 2012 (2012), Article ID 206179, doi: 10.1155/2012/206179.

Compartmental pharmacokinetics of immediate release nifedipine in pregnancy: Variability in absorption

Nader, A. M., Caritis, S. N., Hebert, M. F., Clark, S. M., Flockhart, D. A., & Quinney, S. K. (2012). Compartmental pharmacokinetics of immediate release nifedipine in pregnancy: Variability in absorption. Clinical Pharmacology and Therapeutics, 91(S1), PIII-109,

A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: Predicting changes in midazolam and nifedipint pharmacokinetics

Quinney, S. K., Mohamed, A. N., Hebert, M. F., Haas, D. M., Clark, S., Umans, J. G., Caritis, S. N., & Li, L. (2012). A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: Predicting changes in midazolam and nifedipint pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology, 1: e2, doi: 10.1038/psp.2012.5. (PMID: 23835882)